Long-Term Efficacy of Guideline-Followed Treatment in Patients with Livedoid Vasculopathy: A Single-Center Study

Carina Hillgruber1, Carolin Mitschang1, Maria Eveslage2

  • 1Department of Dermatology, University of Muenster, Muenster, Germany.

Advances in Wound Care
|November 20, 2025
PubMed

Insights

Long-term anticoagulation therapy, including rivaroxaban, effectively manages livedoid vasculopathy symptoms like pain and disease activity. This guideline-adherent treatment significantly improves patients

Area of Science:

  • Dermatology
  • Vascular Medicine
  • Pharmacology

Background:

  • Livedoid vasculopathy is a painful skin condition causing leg ulcerations and scarring (atrophie blanche) due to microcirculation thrombosis.
  • Current treatment options are limited, with no approved therapies, necessitating off-label use.
  • The German S1 guideline recommends anticoagulation as first-line therapy.

Purpose of the Study:

  • To evaluate the long-term efficacy of guideline-adherent anticoagulation treatment for livedoid vasculopathy.
  • To assess the impact of treatment on pain, disease activity, quality of life, and daily life.

Main Methods:

  • A single-center, follow-up study of 26 patients with livedoid vasculopathy.
  • Patients received treatment according to the German S1 guideline (anticoagulants like rivaroxaban).
  • Data collected via questionnaire on demographics, treatment, disease course, quality of life (DLQI), and daily impact.

Main Results:

  • Prolonged guideline-followed treatment effectively managed pain and disease activity in livedoid vasculopathy patients.
  • Patients reported high therapy satisfaction and sustained improvements in quality of life.
  • The study analyzed treatment efficacy over periods ranging from 3 to over 24 months.

Conclusions:

  • Guideline-adherent anticoagulation therapy, including rivaroxaban, is an effective long-term treatment for livedoid vasculopathy.
  • This approach leads to significant improvements in patient outcomes and quality of life.

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
443
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
301
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
427
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
268
Endocarditis III: Medical Management01:18

Endocarditis III: Medical Management

Infective endocarditis management involves a multifaceted approach encompassing infection prevention, lifestyle modifications, pharmacological therapy, and surgical management.Infection Prevention:Hand Hygiene: Thorough handwashing is crucial to prevent the spread of infection. Hand hygiene should be performed regularly, especially before and after using the restroom.Oral Hygiene: Good oral hygiene is essential. It includes brushing teeth immediately after waking up and before bed, flossing...
200
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
229